Baylor College of Medicine

NSABP FB-12: Neoadjuvant AC Followed by Weekly Paclitaxel Plus Pertuzumab and Trastuzumab in Patients with HER2-negative Breast Cancer (H-43487)



The main purpose of this study is to look at the safety and effectiveness of the standard anti-HER2-targeted therapies (trastuzumab and pertuzumab) when given before surgery with the standard chemotherapy (paclitaxel) for patients whose breast cancer is HER2-negative by standard tests but shows abnormal HER2 signaling activity based on further special testing performed only for the study. These results may predict whether or not this breast cancer type will respond to treatment with trastuzumab and pertuzumab.

IRB: H-43487




Back to topback-to-top